Private company

Adcock Ingram

South African pharmaceutical company

Adcock Ingram is a South African pharmaceutical manufacturer listed on the Johannesburg Stock Exchange. Adcock Ingram manufactures and markets healthcare products to both the private and public sectors.2 From Wikipedia, CC BY-SA 4.0

Last updated Oct 16, 2026.

Overview

1891Founded1
  • Tickeron Johannesburg Stock Exchange1
  • Industryhealth care1
  • HeadquartersJohannesburg1
  • Websitewww.adcock.com
  • Legal formpublic company1
  • Listed onJohannesburg Stock Exchange (AIP)1

Adcock Ingram is a South African pharmaceutical manufacturer listed on the Johannesburg Stock Exchange. Adcock Ingram manufactures and markets healthcare products to both the private and public sectors.2

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

90.2%Gross margin4
-47.0%Operating margin4
-49.2%Net margin4
22.3%Revenue growth, 20254
$5.3MFree cash flow4

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

License and Maintenance brought in 83% of the revenue Adcock Ingram broke down this way in fiscal 2025.

  1. License and Maintenance$63.9M483%up 21% from 2024
  2. Variable Royalties And Other$6.7M49%up 37% from 2024
  3. Royalty$6.6M49%up 50% from 2024
Products and services by year
Products and services20242025
License and Maintenance$52.8M$63.9M
Variable Royalties And Other$4.9M$6.7M
Royalty$4.4M$6.6M

Regions

United States brought in 40% of the revenue Adcock Ingram broke down this way in fiscal 2025.

  1. United States$28.0M440%up 29% from 2024
  2. China$17.3M424%up 2% from 2024
  3. South Korea$8.6M412%up 52% from 2024
  4. Other Asia$7.8M411%up 46% from 2024
  5. Europe And Middle East$7.7M411%up 6% from 2024
  6. Other Americas$1.3M42%up 36% from 2024
Regions by year
Regions20242025
United States$21.7M$28.0M
China$16.9M$17.3M
South Korea$5.6M$8.6M
Other Asia$5.3M$7.8M
Europe And Middle East$7.2M$7.7M
Other Americas$955.0K$1.3M

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue10¢$6.9M
  • Research and development71¢$49.9M
  • Other costs17¢$12.3M
  • Income tax2¢$1.5M

Out of $70.6M in revenue.4 The company lost money this year.

Where each dollar of operating cash went, fiscal 2025

  • Capital spending21¢$1.4M
  • Kept or used elsewhere79¢$5.3M

Out of $6.7M of cash from operations.4

Financial statements

Revenue56784$70.6M in 2025+122% since 2020
0$20.0M$40.0M$60.0M$80.0M2020: $31.8M$31.8M20202021: $37.9M$37.9M2021+19%2022: $50.4M$50.4M2022+33%2023: $53.7M$53.7M2023+7%2024: $57.7M$57.7M2024+8%2025: $70.6M$70.6M2025+22%
Gross profit56784$63.7M in 2025+110% since 2020
0$20.0M$40.0M$60.0M$80.0M2020: $30.3M$30.3M20202021: $34.1M$34.1M2021+13%2022: $46.1M$46.1M2022+35%2023: $48.6M$48.6M2023+5%2024: $51.8M$51.8M2024+7%2025: $63.7M$63.7M2025+23%
Operating income56784-$33.1M in 2025+777% since 2020
-$40.0M-$30.0M-$20.0M-$10.0M02020: -$3.8M-$3.8M20202021: -$21.8M-$21.8M2021+476%2022: -$28.9M-$28.9M2022+33%2023: -$35.1M-$35.1M2023+22%2024: -$31.6M-$31.6M2024−10%2025: -$33.1M-$33.1M2025+5%
Net income56784-$34.7M in 2025+966% since 2020
-$40.0M-$30.0M-$20.0M-$10.0M02020: -$3.3M-$3.3M20202021: -$23.4M-$23.4M2021+617%2022: -$27.4M-$27.4M2022+17%2023: -$36.9M-$36.9M2023+35%2024: -$33.6M-$33.6M2024−9%2025: -$34.7M-$34.7M2025+3%

Every line of the income statement in the latest annual report, as filed.4

Period ending2025-12-312024-12-31
Total revenue$70.6M$57.7M
Cost of revenue$6.9M$6.0M
Gross profit$63.7M$51.8M
Research and development$49.9M$45.0M
Sales and marketing$26.8M$20.8M
General and administrative$20.1M$17.6M
Total operating expenses$96.8M$83.4M
Loss from operations-$33.1M-$31.6M
Interest expense-$193.0K-$244.0K
Other income (expense), net$2.9M$3.4M
Loss before income taxes and loss from equity method investment-$30.5M-$28.4M
Loss from equity method investment, net of tax$2.8M$2.7M
Loss before provision for income taxes-$33.3M-$31.1M
Provision for income taxes$1.5M$2.5M
Net loss-$34.7M-$33.6M
Net loss per share attributable to common stockholders, basic (in dollars per share)-$0.82-$0.86
Net loss per share attributable to common stockholders, diluted (in dollars per share)-$0.82-$0.86
Weighted average shares used in computing per share amounts, basic (in shares)42.3M shares38.9M shares
Weighted average shares used in computing per share amounts, diluted (in shares)42.3M shares38.9M shares

Compare Adcock Ingram with another company

The story

Adcock Ingram started as a pharmacy in Krugersdorp operating under the name EJ Adcock Pharmacy in 1890. Krugersdorp at the turn of the century was a "bustling pioneer town". In the early 1900s, Hyme Tannenbaum was apprenticed to then owner, Jack Blair. Hyme's brothers Jack, Len and Archie soon followed him into the pharmacy, which they eventually bought. Beginning with this one small pharmacy, the Tannenbaum brothers built a cross-country chain of retail pharmacies, a pharmaceutical and toiletry manufacturing giant and a highly respected South African success story. Adcock Ingram was first listed on the Johannesburg Stock Exchange in 1950, the first pharmaceutical company to list on the exchange.

The company began internationalisation in the 1990s, beginning with the United Kingdom and Australia, the former meant to be a springboard into Europe.

The company was sold to Tiger Brands for R3.4 billion, and became a wholly owned subsidiary in 2000. However, Adcock had been considered a subsidiary of Tiger Brands since 1978. The relationship with Tiger Brands enabled acquisitions in the 1980s such as the Mer-National division of Dow Chemicals Africa; a 40% share of Baxter's Critical Care Division; and acquisitions of Restan Laboratories and the South African interests of Sterling Winthrop. The company's acquisitions continued into the 1990s with Lepping, Laser, Pharmatech, Zurich Pharmaceuticals, Covan Pharmaceuticals and Salters. A merger between Adcock and Premier Pharmaceuticals took place in 1996, which placed Adcock as "the leading supplier of health care products in South Africa." 2001 saw Adcock's acquisition of medical diagnostics firm Steri-Lab, and Robertsons Homecare's acquisition came in 2003.

By 2005, Adcock revenues constituted half of all revenues for parent firm Tiger Brands. However, growing friction between Adcock's portfolio and the strategic direction charted by Tiger led to Tiger's effective termination in investment in Adcock, which eventually led to divestment of Adcock in 2008, which was shortly followed by Adcock's relisting on the JSE exchange as an independent firm.

From Wikipedia’s article on Adcock Ingram, shared under CC BY-SA 4.0.3

Timeline

  1. 1891Founded Founded1